Podcasts about Atrial fibrillation

The latest Nursing Australia News (02:15) Global workforce warning, Aussie nursing wins, cheeky pill pilfer, and UK pay revolt.Wound Care - The Golden Rules (04:45) Jess Tully is joined by the wound care specialist Melissa Freeman to break down the golden rules of wound care — whether you're managing chronic ulcers, surgical sites, discover eye-opening principles you can apply to practice.Atrial Fibrillation (14:20) It's estimated that 500,000 Australians have been diagnosed with AF. While this is only 2% of the population, the impact of undiagnosed and undertreated AF can be catastrophic. Dr Kate Annear rejoins Nursing Australia Discover info on AF and more at the Quality Use of Medicines Hub  Join The Obesity Collective in shifting the conversation on weight and health. Access free resources today at theobesitycollective.org.au   Discover the Life Program Discover info on AF and more at the Quality Use of Medicines Hub   FLORENCE App by APNA Subscribe to The Connect (our weekly newsletter) Click here to get in touch with Nursing Australia (send a text for free from anywhere in the world) #askusanything Hosted & Produced by: Matthew St Ledger & Leith Alexander Produced by: Leith Alexander & Matthew St Ledger

Which brand of fish oil do you recommend lately?What supplements can help with ankle pain, specifically perineal tendonitis?Aren't doctors opening themselves up to a lawsuit by not using superior methods of cancer detection?Would magnesium help for atrial fibrillation caused by a heart valve replacement? What do you recommend for severe rheumatoid arthritis?How far apart should I eat any dairy from blueberries so as not to inhibit nutrient absorption?

Melissa E. Middeldorp, MPH, PhD is joined by Thomas F. Deering, BS, MBA, MD, FHRS, CCDS, and T. Jared Bunch, MD, FHRS to discuss a 31-item questionnaire was developed and distributed among healthcare professionals via the EHRA network and social media between 23 September and 21 October 2024. https://www.hrsonline.org/education/TheLead https://academic.oup.com/europace/article/27/4/euaf075/8099191?login=false Host Disclosure(s): M. Middeldorp: Nothing to disclose. Contributor Disclosure(s):   T. Deering: Honoraria/Speaking/Consulting: Sanofi, Pacemate, Pfizer, Inc., Omny Health, Preventice Research: Abbott, Boston Scientific, Medtronic, Biotronik, Biosense Webster, Inc.,  Stock Options - Privately Held: HeartBeam Officer, Trustee, Director, Committee Chair: Board Membership T. Bunch: Honoraria/Speaking/Consulting: Pfizer, Inc. Heart Rhythm Society

This episode covers:  Cardiology this Week: A concise summary of recent studies Atrial fibrillation in heart failure Temperature management following cardiac arrest Statistics Made Easy: Collider bias Host: Emer Joyce Guests: Carlos Aguiar, Christian Hassager, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/1812 Want to watch that extended interview on temperature management following cardiac arrest? Go to: https://esc365.escardio.org/event/1812?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This week please join author Boyoung Joung and Associate Editor Svati Shah as they discuss the article "Proteomic Signatures for Risk Prediction of Atrial Fibrillation." For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20250728.351486

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Association of Race and Ethnicity With Stroke and Mortality Outcomes in Atrial Fibrillation.

Cardiac electrophysiologist Seth Goldbarg, MD, shares how AI can improve outcomes for patients with persistent and longstanding atrial fibrillation by identifying critical areas for ablation. Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

With Francesca Coraducci Marche Polytechnic University of Ancona, Ancona - Italy, Marco Guglielmo, University Medical Center Utrecht, Utrecht - The Netherlands, and Anna Giulia Pavon, Cardiocentro Ticino Institute, Lugano - Switzerland. Link to editorial Link to paper

☕

In atrial fibrillation (A-Fib) and atrial flutter (A-Flutter) the electrical impulse for cardiac contraction is in the atria but isn't the normal pacemaker of the heart, the SA node. The ECG characteristics of A-Fib and A-Flutter. Recognition and treatment of unstable patients in A-Fib/Flutter with rapid ventricular response (RVR).Suggested energy settings for synchronized cardioversion of unstable patients with a narrow complex tachycardia. Team safety when cardioverting an unstable patient in A-FIB/Flutter.Adenosine's role for stable SVT patients with underlying atrial rhythms.Treatment of stable patients in A-Fib/Flutter with RVR.For other medical podcasts that cover narrow complex tachycardias, visit the pod resource page at passacls.com. Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Practice ECG rhythms at Dialed Medics - https://dialedmedics.com/Free Prescription Discount Card - Download your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vipPass ACLS Web Site - Episode archives & other ACLS-related podcasts: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

Oral antiarrhythmics have limited efficacy and significant risks Catheter ablation is now a first-line option in suitable patients Newer ablation technology - Pulsed field ablation (PFA) is safer and faster Anticoagulation decisions remain based on stroke risk, not ablation status Genuine post-procedural issues may be benign Ongoing healthcare professional role - Blood pressure and risk factor control The questions answered in this podcast are listed below.They were compiled by GPs and health professionals around Australia who attended Healthed’s face-to-face seminars. How effective are oral antiarrhythmic medications? Does this cure atrial fibrillation? What is the current state of ablation technology? Can you explain what you mean by "rapid" and provide an example of how long a procedure typically takes? Does reduced scarring decrease the likelihood or complexity of needing a repeat ablation? What are some of the contraindications in terms of structurally abnormal heart that would be contraindications for the patient? How should atrial fibrillation be approached in patients with severe ischaemic heart disease? Does this complicate treatment? If a patient has an AF ablation, can they come off my anticoagulant? How do you manage patient’s embolic issues? How soon after the procedure can patients typically be discharged? Following successful AF suppression, is it possible for patients to stop taking DOACs or other anticoagulants? After discharge, how soon should patients follow up with their GP? What should the GP monitor and what should be communicated back to the specialist? When will you consider AV node ablation and insertion of a pacemaker? Host: David Lim | Total Time: 44 mins Expert: Prof Rukshen Weerasooriya, Sub-specialist Cardiac Electrophysiologist Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.

With Frank Flachskampf, Uppsala University, Uppsala - Sweden, and James Thomas, Northwestern University, Chicago - USA.  Link to editorial  Link to paper  

Jafar has a history of atrial fibrillation and reports occasional fatigue and palpitations. His resting heart rate is 96 bpm and irregular, and he takes a beta-blocker. During a six-minute walk test, he experiences mild shortness of breath but completes the test without difficulty. Which consideration is MOST important when developing this patient's exercise program?A) Monitor for a target heart rate based on age-predicted max heart rateB) Use a perceived exertion scale to guide exercise intensityC) Avoid aerobic exercise due to the risk of arrhythmiasD) Encourage high-intensity intervals to improve cardiovascular functionDOWNLOAD THIS EPISODE'S CHEATSHEET:www.nptecheatsheet.com/atrial-fib

RFK Jr. fires entire vaccine panel, replaces with new picks—a catastrophe for public health, or a clean slate for transparent science? Red yeast rice for cholesterol; Is fish oil a no-no if you have atrial fibrillation? Study finds GLP-1 drugs associated with heightened macular degeneration risk; A novel nutrient—OEA—shows promise for reversing metabolic disorders, enhancing satiety.

Heart attacks & strokes are down, but guess what's rising? ⚡ Atrial fibrillation,

Atrial-Fibrillation ຫຼື AF ເປັນໂຣກທີ່ຈັງຫວະການເຕັ້ນຂອງຫົວໃຈ ທີ່ປົກກະຕິ ແລະສມ່ຳສເມີ ຖືກປ່ຽນແທນດ້ວຍ ຄວາມວຸ່ນວາຍທາງໄຟຟ້າ ໃນຫ້ອງທາງເທິງຂອງຫົວໃຈ ຊຶ່ງເຮັດໃຫ້ປະສິດທິພາບ ຂອງການສູບເລືອດຂອງຫົວໃຈ ຫລຸດລົງຢ່າງຫລວງຫລາຍ. Atrial-Fibrillation -ຫລື AF- ສາມາດສົ່ງຜົນກະທົບຕໍ່ແຕ່ລະຄົນ ໃນທາງທີ່ແຕກຕ່າງກັນ. AF ຍັງເປັນສາເຫດຂອງ ປະມານຫນຶ່ງໃນສີ່ ກໍຣະນີ ຂອງໂຣກເສັ້ນເລືອດໃນສມອງ (Strokes) ແລະຄວາມສ່ຽງສູງ ຕໍ່ພາວະສມອງເສື່ອມ.

حدود نیم میلیون آسترالیایی با مریضی فیبریلاسیون دهلیزی یا Atrial Fibrillation که شایع‌ترین نوع بی‌نظمی ضربان قلب است، زندگی می‌کنند. اما تقریباً ۳۰ درصد مبتلایان در مورد آن نمی‌دانند. این مسأله می‌تواند پیامدهای جدی برای صحت آن‌ها، بخصوص در دوره کلان‌سالی به همراه داشته باشد؛ چون این وضعیت خطر ابتلاء به سکته مغزی و زوال عقل را افزایش می‌دهد.

We covered a paper in episode 81 that suggested treating atrial fibrillation with rapid ventricular response in the field could lower mortality. But it also drops BP a bit. Could pretreating these patients with calcium lower the risk of hypotension? Dr Jarvis puts on his nerd hat and uses Bayesian analysis to assess a new randomized, placebo-controlled study that looked at just this thing. Why is he going off on this Bayes thing? Because he's been reading a couple of book on it and wanted to take it for a spin.  Tables:  Charts: Bayesian Distributions: Citation: 1.     Az A, Sogut O, Dogan Y, Akdemir T, Ergenc H, Umit TB, Celik AF, Armagan BN, Bilici E, Cakmak S: Reducing diltiazem-related hypotension in atrial fibrillation: Role of pretreatment intravenous calcium. The American Journal of Emergency Medicine. 2025;February;88:23–8.2.     Fornage LB, O'Neil C, Dowker SR, Wanta ER, Lewis RS, Brown LH: Prehospital Intervention Improves Outcomes for Patients Presenting in Atrial Fibrillation with Rapid Ventricular Response. Prehospital Emergency Care. doi: 10.1080/10903127.2023.2283885 (Epub ahead of print).3.     Kolkebeck T, Abbrescia K, Pfaff J, Glynn T, Ward JA: Calcium chloride before i.v. diltiazem in the management of atrial fibrillation. The Journal of Emergency Medicine. 2004;May 1;26(4):395–400.4.     Chivers T: Everything Is Predictable: How Bayes' Remarkable Theorem Explains the World. Weidenfeld & Nicolson, 2024.5.     McGrayne SB: The Theory That Would Not Die. how Bayes' Rule Cracked The Enigma Code, Hunted Down Russian Submarines & Emerged Triumphant From Two Centuries of Controversy. New Haven, CT, Yale University Press, 2011. FAST25 | May 19-21, 2025 | Lexington, KY

Dr. Emile Daoud, Deputy Editor of JACC Clinical Electrophysiology discusses Premature Ventricular Complexes after Ablation for Paroxysmal Atrial Fibrillation and Recurrent Atrial Arrhythmias: admIRE Subanalysis.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Healthcare Expenditure on Atrial Fibrillation in the United States: The Medical Expenditure Panel Survey 2016 to 2021.

Be alert to atypical symptoms, such as fatigue or reduced exercise tolerance, particularly in younger patients Serial Holter monitoring and attention to atrial ectopy burden can guide suspicion Wearables like the Apple Watch and Samsung Galaxy Watch are effective adjuncts for rhythm detection Early ablation may be appropriate, even in younger patients with a low CHA₂DS₂-VASc score, if they are symptomatic Collaboration between healthcare professionals and Electrophysiologists is essential to optimise patient outcomes The questions answered in this podcast are listed below.They were compiled by GPs and health professionals around Australia who attended Healthed’s face-to-face seminars. Atrial fibrillation – it's not an uncommon arrhythmia in Australia, is it? What are some of the environmental factors that have been identified as contributing to atrial fibrillation, apart from COVID? Why are we picking up more cases of atrial fibrillation? Are patients becoming more symptomatic? Obstructive sleep apnoea doesn't cause atrial fibrillation, but can it make it permanent? How can the pulmonary veins cause a cardiac arrhythmia? What are the indications for treating patients with ablation? How is it managed? What's the current thinking? How far should a healthcare professionals go in trying to detect atrial fibrillation in patients with unusual symptoms? Host: David Lim | Total Time: 32 mins Expert: Prof Rukshen Weerasooriya, Sub-specialist Cardiac Electrophysiologist Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.

Assessing Recurrence Following Pulsed Field Ablation for Atrial Fibrillation   Guest: Nicholas Tan, M.D., M.S. Host: Anthony H. Kashou, M.D.   Pulsed field ablation has been rapidly adopted across the United States since FDA approval was granted 1 year ago, due to its excellent acute efficacy, favorable safety profile, and fast workflow. However, recurrences post-ablation are comparable to that of previously established modalities, making this a significant hurdle that has yet to be overcome. Changes to mapping/ablation strategies, updates to PFA parameters, autonomic modulation, and combination modality ablations (PFA/RFA) offer some avenues for improvement   Topics Discussed:  What is pulsed field ablation (PFA) and how does it differ from previously established modalities of ablation such as radiofrequency and cryoablation? What are the recurrence rates post-PFA and how do they compare with other modalities? In patients who undergo redo ablations following an index PFA procedure, what are the most common causes (i.e. reconnection of pulmonary veins versus new sites)? How do you think PFA will evolve in the coming years   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

With Damiano Fedele, University of Bologna, Bologna - Italy and University Medical Center Utrecht - The Netherlands, Marco Guglielmo, University Medical Center Utrecht, Utrecht - The Netherlands, and Anna Giulia Pavon, Cardiocentro Ticino Institute, Lugano - Switzerland. Link to editorial Link to paper 

BUFFALO, NY — May 14, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 4, on April 10, 2025, titled “Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation.” In this study, first author Masahiko Takahashi and corresponding author Keisuke Okawa led a research team from Kagawa Prefectural Central Hospital and Hyogo Medical University that investigated whether Factor Xa inhibitors (Xa-Is)—a type of blood thinner—can reduce the risk of heart-related complications in patients over 80 with nonvalvular atrial fibrillation (NVAF). The study found that patients using Xa-Is experienced significantly fewer cardiovascular problems than those on other anticoagulants. This finding is especially relevant, as older adults face a high risk of both stroke and heart disease. Atrial fibrillation is a common heart rhythm disorder, particularly in the elderly, that increases the risk of blood clots, heart failure, and stroke. Anticoagulants are often prescribed to prevent clots, but not all types have the same effects on heart health. This study focused on comparing Xa-Is—specifically rivaroxaban, apixaban, and edoxaban—with commonly used drugs such as warfarin and dabigatran. Researchers followed more than 1,000 patients aged 80 and above for up to five years to assess the long-term impact of these medications on cardiovascular outcomes. Patients who used Xa-Is had significantly lower rates of heart failure, artery disease, and cardiovascular death. The risk of cardiovascular problems in the Xa-I group was less than half that of those on non-Xa-I medications. These benefits remained even after adjusting for factors like age, existing heart conditions, and kidney function. Additionally, stroke and all-cause death rates were notably lower in the Xa-I group. “Xa-Is may be useful for not only anticoagulation but also the prevention of cardiovascular events in very old patients with NVAF.” What makes Xa-Is different, according to the researchers, is their ability to inhibit a specific biological pathway—known as Factor Xa–PAR2—that contributes to inflammation, fibrosis, and damage in blood vessels and heart tissue. This effect extends beyond their traditional role in preventing blood clots. Although the study was conducted at a single medical center in Japan, its rigorous design and long follow-up period enhance the reliability of the findings for real-world clinical decision-making. While further studies, especially across multiple centers, are needed to confirm the full range of benefits, this study strongly suggests that Xa-Is may offer broader cardiovascular protection for very old patients. The findings could influence how clinicians choose blood thinners for elderly individuals with atrial fibrillation, potentially improving both survival and quality of life in this growing population. DOI - https://doi.org/10.18632/aging.206238 Corresponding author - Keisuke Okawa - k-ookawa@chp-kagawa.jp Video short - https://www.youtube.com/watch?v=YtbYpfVDVDI Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206238 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, Factor Xa inhibitor, atrial fibrillation, older patient, cardiovascular events To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

Join host Michael S. Lloyd, MD, FHRS and episode guests Ante Anic, MD and Konstantinos Vlachos, MD as they discuss the recent article Repeat Procedures after Pulsed Field Ablation for Atrial Fibrillation, the MANIFEST-REDO Study, from Europace. This episode was recorded in-person at EHRA 2025. Bonus video footage of the episode is available on heartrhythm265.org.   https://www.hrsonline.org/education/TheLead https://academic.oup.com/europace/advance-article/doi/10.1093/europace/euaf012/7958418   Host Disclosure(s): M. Lloyd: Honoraria/Speaking/Consulting: Medtronic, Arga Medtech, Circa Scientific Membership on Advisory Committees: Boston Scientific Contributor Disclosure(s): A. Anic: Honoraria/Speaking/Consulting: Boston Scientific Research: Biosense Webster, Inc., AtaCor Medical Inc., Arga Medtech K. Vlachos: Nothing to disclose.

In atrial fibrillation (A-Fib) and atrial flutter (A-Flutter) the electrical impulse for cardiac contraction is in the atria but isn't the normal pacemaker of the heart, the SA node. The ECG characteristics of A-Fib and A-Flutter. Recognition and treatment of unstable patients in A-Fib/Flutter with rapid ventricular response (RVR).Suggested energy settings for synchronized cardioversion of unstable patients with a narrow complex tachycardia. Team safety when cardioverting an unstable patient in A-FIB/Flutter.Adenosine's role for stable SVT patients with underlying atrial rhythms.Treatment of stable patients in A-Fib/Flutter with RVR. For other medical podcasts that cover narrow complex tachycardias, visit the pod resource page at passacls.com. Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Practice ECG rhythms at Dialed Medics - https://dialedmedics.com/Free Prescription Discount Card - Download your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vip/savePass ACLS Web Site - Episode archives & other ACLS-related podcasts: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

Interview with Leonoor F. J. M. Wijdeveld, BSc and Sean J. Jurgens, MD, MSc, PhD, authors of Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation. Hosted by Sharlene Day, MD. Related Content: Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation Genetic Testing in Early-Onset Atrial Fibrillation

Interview with Leonoor F. J. M. Wijdeveld, BSc and Sean J. Jurgens, MD, MSc, PhD, authors of Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation. Hosted by Sharlene Day, MD. Related Content: Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation Genetic Testing in Early-Onset Atrial Fibrillation

This special electrophysiology-themed issue of JACC, summarized by Dr. Valentin Fuster, dives into cutting-edge research on atrial fibrillation, pulsed field ablation, sudden cardiac arrest in athletes, and preventive strategies in congenital heart disease. From new therapies like finerenone to breakthrough mapping techniques, this episode captures the evolving sophistication and promise of arrhythmia management in modern cardiology.

This special electrophysiology-themed issue of JACC, summarized by Dr. Valentin Fuster, dives into cutting-edge research on atrial fibrillation, pulsed field ablation, sudden cardiac arrest in athletes, and preventive strategies in congenital heart disease. From new therapies like finerenone to breakthrough mapping techniques, this episode captures the evolving sophistication and promise of arrhythmia management in modern cardiology.

This week on Health and Longevity, Dr. John Westerdahl's featured guest is Steven Ryan, Ph.D. - Author of Beat Your A-Fib - The Essential Guide to Finding Your Cure. Dr. Ryan discusses Atrial Fibrillation, an emerging new epidemic in cardiovascular disease. A former A-Fib patient himself, Dr. Ryan is a noted healthcare educator and advocate for patients suffering from Atrial Fibrillation.

In this podcast, Dr. Valentin Fuster reviews the impact of catheter ablation on atrial fibrillation progression, summarizing a state-of-the-art article published in JACC. It explores how catheter ablation modifies the disease's mechanisms, reduces progression to persistent atrial fibrillation, and improves cardiovascular outcomes, suggesting that earlier intervention leads to better long-term results.

Mark Goddard, Vice President of Clinical Services at InfoBionic.Ai, a leading authority in cardiac remote monitoring. A registered nurse with over 20 years of experience in clinical electrophysiology, Mark has pioneered service lines across ambulatory ECG, cardiac event monitoring, mobile telemetry and heart failure management in hundreds of institutions. He's also a certified Clinical Cardiac Device Specialist with deep knowledge of subcutaneous monitoring and AI-assisted diagnosticsIn this episode, we explore how AI and real-time ECG data are revolutionising arrhythmia detection, heart failure prediction and patient engagement especially for high-risk groups like those with A-Fib. Mark shares practical insights from the front lines of cardiac care, how to tell genuine innovation from AI hype and why the future of diagnostics may lie beyond traditional heart monitoring. We also cover clinical implementation challenges, device design for older populations and the fine line between wellness tracking and medical-grade careTimestamps:[00:00:27] AI-Powered ECG: From Novelty to Necessity[00:03:28] How Clinicians Are Separating Hype from Reality[00:05:07] Why Near Real-Time Beats Traditional ECG Monitoring[00:08:49] A-Fib and the Global Data Gap[00:11:36] When Good Tech Goes Bad: Early Pacemaker Mistakes[00:13:30] Hospitals, Homes and the Future of Cardiac Care[00:19:59] AI vs Machine Learning: What's the Real Difference?Get in touch with Mark - https://www.linkedin.com/in/mark-goddard-035ab427/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

In this episode of Docs in a Pod, host Gina Galaviz sits down with Dr. Rajay Seudath, from Optum - University  to break down atrial fibrillation (AFib)—a common but serious heart rhythm disorder. They'll discuss what causes AFib, its symptoms, potential complications, and the latest treatment options. Whether you're a patient, caregiver, or just curious about heart health, this episode offers expert insights to help you better understand and manage this condition.  Docs in a Pod focuses on health issues affecting adults. Clinicians and other health partners discuss stories, topics and tips to help you live healthier. Docs in a Pod airs on Saturdays in the following cities:  7:00 to 7:30 am CT:  San Antonio (930 AM The Answer)  DFW (660 AM, 92.9 FM [Dallas], 95.5 FM [Arlington], 99.9 FM [Fort Worth])  6:30 to 7:00 pm CT:  Houston (1070 AM/103.3 FM The Answer)  7:00 to 7:30 pm CT:  Austin (KLBJ 590 AM/99.7 FM)  Docs in a Pod also airs on Sundays in the following cities:  1:00-1:30 pm ET:  Tampa (860 AM/93.7FM)   

Host Melissa E. Middeldorp, MPH, PhD, of the University Medical Centre Groningen & University of Adelaide, is joined by Andrea Robinson, MSN, ACNP, from Riverside Methodist Hospital, OhioHealth, and Jeroen ML Hendriks, PhD, RN, of Maastricht University Medical Centre, in this episode. The AF-EduCare trial investigated whether targeted patient education (delivered in-person or online) could reduce unplanned cardiovascular events in patients with atrial fibrillation (AF). The study found that while education improved patient knowledge, medication adherence, and risk factor awareness, it did not significantly reduce cardiovascular hospitalizations, emergency visits, or mortality compared to standard care. However, subgroup analyses suggested that younger patients, those without heart failure, and asymptomatic AF patients might benefit more from in-person education. The findings highlight that while education enhances patient engagement, comprehensive medical management and timely clinical interventions remain the key drivers of improved cardiovascular outcomes in AF care.  Join us for this in-depth conversation about the trial.   https://www.hrsonline.org/education/TheLead https://academic.oup.com/europace/article/27/1/euae211/7964628 Host Disclosure(s): M. Middeldorp: Nothing to disclose. Contributor Disclosure(s): A. Robinson: Honoraria/Speaking/Consulting: Medtronic, Inc., AtriCure, Inc., Biosense Webster, Inc. J. Kendriks: Honoraria/Speaking/Consulting: Biotronik   This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365: https://www.heartrhythm365.org/URL/TheLeadEpisode98

Interview with Steven J. Warach, MD, PhD, author of Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Pragmatic, Response-Adaptive Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation

For this episode we are joined by EBM guru, Dr. Brian Locke, who deftly breaks down all of our statistics questions. Is half dose DOAC as good as full dose DOAC for preventing VTE, and does it reduce bleeding risk? Can procalcitonin reduce duration of antibiotics for infections without compromising mortality rates? Can LLMs like GPT-4 help physicians manage patients better? Can reinforcement learning models predict when to start vasopressin in patients with septic shock? What is the risk of resuming anticoagulation in patients with atrial fibrillation and prior intracerebral hemorrhage? Is high flow nasal cannula as good as non-invasive ventilation for different types of respiratory failure? We answer all these questions and more!Half Dose DOAC for Long Term VTE Prevention (RENOVE)Biomarker-Guided Antibiotic Duration (ADAPT-Sepsis)GPT-4 Assistance for Physician PerformanceOptimal Vasopressin Initiation for Septic Shock (OVISS)DOACs for A fib after ICH (PRESTIGE-AF)High Flow Nasal Cannula vs NIV for Respiratory Failure (RENOVATE)Music from Uppbeat (free for Creators!): https://uppbeat.io/t/soundroll/dope License code: NP8HLP5WKGKXFW2R

This interview features JACC Associate Editor Neha Pagidipati, MD, FACC, speaking with Maria Pabon, MD and Muthu Vaduganathan, MD about their study on finerenone's role in reducing new-onset atrial fibrillation in patients with cardio-kidney metabolic disease. The discussion covers the methodology and findings of a pooled analysis from three major clinical trials, highlighting finerenone's 17% risk reduction in atrial fibrillation, its potential mechanisms, and the need for greater diversity in clinical trial populations. They also touch on comparative evidence with other mineralocorticoid receptor antagonists and the broader implications for heart failure management.

YES！我的高股息國際巨星來啦！ 國際級的高股息！？哪一檔這麼給力？ 00963 中信全球高股息，嚴選海外優息企業，掌握全球收益機會，3月首次除息囉！ 上除息行列！打開券商APP，輸入00963，3/17前買進即可參與，趕緊下單去！ https://user285523.pse.is/79hhbf -- 高雄美術特區3-4房全新落成，《惟美術》輕軌C22站散步即到家，近鄰青海商圈，卡位明星學區，徜徉萬坪綠海。 住近美術館，擁抱優雅日常，盡現驕傲風範！美術東四路29號 07-553-3838 https://user285523.pse.is/79p2pd －－－－以上訊息由 SoundOn 動態廣告贊助商提供－－－－ 飛碟聯播網《飛碟早餐 唐湘龍時間》2025.03.25 週二醫療保健單元 專訪：藥理學教授｜潘懷宗 主題：新抗凝血藥-阿貝西單抗的亮眼功效 心房顫動（Atrial Fibrillation）是心律不整最常見的原因，每個人終其一生會罹患心房顫動的機率高達25％。如果不就醫治療，好好保養，最嚴重的併發症為阻塞型腦中風和心臟衰竭，甚至失去生命，不可大意。 抗凝血劑一方面降低血栓形成，預防中風和週邊血管栓塞，但也會有出血併發症增加的擔憂，如果能有一款藥，既能降低血栓形成，又能減少出血併發症，那就是再好不過了。美國哈佛大學布萊根婦女醫院的研究人員針對新一型的抗凝血劑Abelacimab （阿貝西單抗）進行研究，並與現行的標準藥物Xarelto（拜瑞妥）互相比較，ClinicalTrials.gov編號為 NCT04755283。結果發現其出血併發症大幅度減少，相當令人滿意並超出預期，遂根據數據監測委員會的建議，提前完成了此次的臨床試驗，成果也已經發表在2025年1月的《新英格蘭醫學期刊》上。 「阿貝西單抗」不僅在心房顫動患者身上表現突出，也在膝關節置換中，優異亮眼，與現行預防靜脈血栓的克立生注射劑（Enoxaparin）相比，注射單劑量150毫克「阿貝西單抗」可使靜脈血栓發生率再降低80％，且不會增加出血風險。目前研究小組正在進一步實施的3期臨床試驗中，針對高風險、不適合使用現行抗凝血劑的心房顫動患者，給予150毫克劑量的「阿貝西單抗」或安慰劑，進行中風發生率和出血性事件的比較，希望能對這些原本無法用藥的病患，也能有所幫助，讓我們共同期望此藥正式上市的好消息。 潘懷宗教授 完整文章 https://www.chinatimes.com/opinion/20… #abelacimab #心房顫動#抗凝血#凝血劑#心臟#衰竭#中風#血栓#血管 ▶ 《飛碟早餐》FB粉絲團  / ufobreakfast  ▶ 飛碟聯播網FB粉絲團  / ufonetwork921  ▶ 網路線上收聽 http://www.uforadio.com.tw ▶ 飛碟APP，讓你收聽零距離 IOS：https://reurl.cc/3jYQMV Android：https://reurl.cc/5GpNbR ▶ 飛碟Podcast SoundOn : https://bit.ly/30Ia8Ti Apple Podcasts : https://apple.co/3jFpP6x Spotify : https://spoti.fi/2CPzneD KKBOX：https://reurl.cc/MZR0K4 -- Hosting provided by SoundOn

Send us a textWelcome back Rounds Table Listeners! In this throwback episode, Drs. Mike and John Fralick chat about five important research studies published in 2023:Hydrocortisone in Severe Community-Acquired Pneumonia (0:00 – 5:39).Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes (5:40 – 8:48).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (8:49 – 12:29).Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection (12:30 – 17:49).Early versus Later Anticoagulation for Stroke with Atrial Fibrillation (17:50 – 23:38).And for the Good Stuff:The Beckham docuseries on Netflix (23:39 – 24:15)Upside Drinks (24:16 – 26:04).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods